Managing Weight Gain on Antidepressants

Initial Assessment and Monitoring

Document baseline weight and BMI before continuing antidepressant therapy, then monitor weight monthly for the first 3 months, followed by quarterly monitoring during continued treatment, as recommended by the American Medical Association 1, 2
Intervene if weight gain exceeds 2 kg in one month or ≥7% increase from baseline body weight, according to the American Medical Association 1, 2
Screen for other medications that may be contributing to weight gain, including other antidepressants, anticonvulsants, corticosteroids, antidiabetic agents, beta-blockers, and progesterone-based contraceptives, as suggested by the American Medical Association 2

The American Medical Association recommends implementing dietary counseling and structured exercise programs as the first-line intervention 1, 2
Counsel on portion control and reduction/elimination of ultraprocessed foods and sugar-sweetened beverages, with increased fruit and vegetable intake, as recommended by the American Medical Association 1
Consider high-protein meal replacements for 1-2 meals daily, which produces a mean weight difference of -1.44 kg versus diet alone, according to the American Medical Association 1
Prescribe 150-300 minutes weekly of moderate-intensity aerobic exercise, which produces mean weight loss of 2-3 kg, as suggested by the American Medical Association 1, 2
Add resistance training 2-3 times weekly to preserve lean muscle mass, as recommended by the American Medical Association 1, 2
Encourage use of wearable activity trackers, which can increase activity by 1800 steps daily and produce 0.5-1.5 kg weight loss, according to the American Medical Association 1, 2

If lifestyle modifications prove inadequate after 3 months, add metformin 1000 mg total daily dose, which produces a mean weight reduction of 3.27 kg, as recommended by the American Medical Association 1, 2
Topiramate 100 mg daily can be considered, producing mean weight difference of -3.76 kg, according to the American Medical Association 1, 2
GLP-1 receptor agonists can be initiated when lifestyle modifications prove inadequate, particularly in patients with BMI ≥30 or BMI ≥27 with weight-related complications, as suggested by the American Medical Association 1, 2

If weight gain remains problematic despite interventions and the patient's depression is well-controlled, consider switching to bupropion, fluoxetine, or sertraline, which are more weight-neutral or associated with weight loss, as recommended by the American Medical Association 1
Bupropion is the only antidepressant consistently associated with weight loss rather than weight gain, according to the American Medical Association 1
Fluoxetine and sertraline are associated with weight loss with short-term use and weight neutrality with long-term use, as suggested by the American Medical Association 1
Avoid switching to paroxetine, amitriptyline, or mirtazapine, which have high weight gain risk, according to the American Medical Association 1

In patients with depression and concurrent appetite loss/weight loss, some degree of weight gain may be therapeutically beneficial, as noted by the American Medical Association 1
For patients with obesity or overweight with cardiovascular risk factors, weight loss treatment is indicated regardless of antidepressant choice, according to the American Heart Association 3